{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:03:05Z","timestamp":1785859385090,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-025-05044-1","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:49:42Z","timestamp":1749530982000},"page":"50-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort"],"prefix":"10.1007","volume":"51","author":[{"given":"Wyanne","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natally","family":"Horvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlie","family":"Sigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Erdem","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Chernyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"5044_CR1","doi-asserted-by":"crossref","unstructured":"1. Qiu S, Cai J, Yang Z, He X, Xing Z, Zu J, et al. Trends in hepatocellular carcinoma mortality rates in the US and projections through 2040. JAMA Netw Open. 2024 Nov 4;7(11):e2445525.","DOI":"10.1001\/jamanetworkopen.2024.45525"},{"key":"5044_CR2","doi-asserted-by":"crossref","unstructured":"2. Dantzer C, Dif L, Vach\u00e9 J, Basbous S, Billottet C, Moreau V. Specific features of \u00df-catenin-mutated hepatocellular carcinomas. Br J Cancer. 2024 Sep 11;","DOI":"10.1038\/s41416-024-02849-7"},{"key":"5044_CR3","doi-asserted-by":"crossref","unstructured":"3. Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019 Sep;71(3):616\u201330.","DOI":"10.1016\/j.jhep.2019.06.001"},{"key":"5044_CR4","doi-asserted-by":"crossref","unstructured":"4. Lu G, Lin J, Song G, Chen M. Prognostic significance of CTNNB1 mutation in hepatocellular carcinoma: a systematic review and meta-analysis. Aging (Albany NY). 2023 Sep 20;15(18):9759\u201378.","DOI":"10.18632\/aging.205047"},{"key":"5044_CR5","doi-asserted-by":"crossref","unstructured":"5. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clin Cancer Res. 2019 Apr 1;25(7):2116\u201326.","DOI":"10.1158\/1078-0432.CCR-18-2293"},{"key":"5044_CR6","doi-asserted-by":"crossref","unstructured":"6. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 Dec 1;78(6):1922\u201365.","DOI":"10.1097\/HEP.0000000000000466"},{"key":"5044_CR7","doi-asserted-by":"crossref","unstructured":"7. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol. 2011 Oct;21(10):2056\u201366.","DOI":"10.1007\/s00330-011-2165-8"},{"key":"5044_CR8","doi-asserted-by":"crossref","unstructured":"8. Kubo A, Suda G, Kimura M, Maehara O, Tokuchi Y, Kitagataya T, et al. Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. Cancers (Basel). 2021 Jul 20;13(14).","DOI":"10.3390\/cancers13143633"},{"key":"5044_CR9","doi-asserted-by":"crossref","unstructured":"9. de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023 Dec 1;83(23):3861\u20137.","DOI":"10.1158\/0008-5472.CAN-23-0816"},{"key":"5044_CR10","doi-asserted-by":"crossref","unstructured":"10. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401\u20134.","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"5044_CR11","doi-asserted-by":"crossref","unstructured":"11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2;6(269):pl1.","DOI":"10.1126\/scisignal.2004088"},{"key":"5044_CR12","doi-asserted-by":"crossref","unstructured":"12. Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY). 2018 Jan;43(1):56\u201374.","DOI":"10.1007\/s00261-017-1325-y"},{"key":"5044_CR13","doi-asserted-by":"crossref","unstructured":"13. Bao X, Wang K, Liu M, Li B, Wang H, Jin K, et al. Characterization of genomic alterations in colorectal liver metastasis and their prognostic value. Front Cell Dev Biol. 2021;9:760618.","DOI":"10.3389\/fcell.2021.760618"},{"key":"5044_CR14","doi-asserted-by":"crossref","unstructured":"14. Bao Y, Li J-X, Zhou P, Tong Y, Wang L-Z, Chang D-H, et al. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization. Radiology. 2023 Aug;308(2):e230457.","DOI":"10.1148\/radiol.230457"},{"key":"5044_CR15","doi-asserted-by":"crossref","unstructured":"15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159\u201374.","DOI":"10.2307\/2529310"},{"key":"5044_CR16","doi-asserted-by":"crossref","unstructured":"16. Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. In Vivo. 2019;33(5):1411\u201320.","DOI":"10.21873\/invivo.11618"},{"key":"5044_CR17","doi-asserted-by":"crossref","unstructured":"17. Li H-M, Huang W, Hu C, Zhang Z-S, Xiao Y-D, Wang T-C. Prognostic Factors for Patients with Proliferative Hepatocellular Carcinoma After Liver Resection. J Hepatocell Carcinoma. 2023 Nov 20;10:2059\u201371.","DOI":"10.2147\/JHC.S440636"},{"key":"5044_CR18","doi-asserted-by":"crossref","unstructured":"18. Lu M, Yan Z, Qu Q, Zhu G, Xu L, Liu M, et al. Diagnostic Model for Proliferative HCC Using LI-RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI-ICI Combination. J Magn Reson Imaging. 2024 Apr 22;","DOI":"10.1002\/jmri.29400"},{"key":"5044_CR19","doi-asserted-by":"crossref","unstructured":"19. Kang H-J, Kim H, Lee DH, Hur BY, Hwang YJ, Suh K-S, et al. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology. 2021 Sep;300(3):572\u201382.","DOI":"10.1148\/radiol.2021204352"},{"key":"5044_CR20","doi-asserted-by":"crossref","unstructured":"20. Cannella R, Furlan A. Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY). 2018 Jul;43(7):1847\u20138.","DOI":"10.1007\/s00261-017-1372-4"},{"key":"5044_CR21","doi-asserted-by":"crossref","unstructured":"21. Kudo M. Atypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity. Intervirology. 2004;47(3\u20135):227\u201337.","DOI":"10.1159\/000078475"},{"key":"5044_CR22","doi-asserted-by":"crossref","unstructured":"22. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002 Jul 18;21(31):4863\u201371.","DOI":"10.1038\/sj.onc.1205591"},{"key":"5044_CR23","doi-asserted-by":"crossref","unstructured":"23. Li M, Fan Y, You H, Li C, Luo M, Zhou J, et al. Dual-Energy CT Deep Learning Radiomics to Predict Macrotrabecular-Massive Hepatocellular Carcinoma. Radiology. 2023 Aug;308(2):e230255.","DOI":"10.1148\/radiol.230255"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05044-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:03:43Z","timestamp":1769148223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-05044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["5044"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-05044-1","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflicts of interest: One of authors, Richard K. Do, is currently an advisory board member to Ascelia Pharma. Natally Horvat received lecture honoraria from Bayer (September 2022) and from Guerbet (May 2024), she also served as a clinical consultant advisor for Guerbet (February 2023) and received travel support from Guerbet (February 2023 and May 2024). Alice C. Wei is a member of the DSMB for Histosonics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}